Cited by 163Genetics and Neurodevelopmental DisordersPharmacological Effects and Toxicity StudiesAlzheimer's disease research and treatments

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome

Open access

Glaze, Daniel G., Neul, Jeffrey L., Kaufmann, Walter E., Berry-Kravis, Elizabeth, Condon, Sean, Stoms, George, Oosterholt, Sean, Della Pasqua, Oscar, Glass, Larry, Jones, Nancy E., Percy, Alan K., Rett 002 Study Group, Glaze, Daniel G., Neul, Jeffrey L., Kaufmann, Walter E., Berry-Kravis, Elizabeth, Condon, Sean, Stoms, George, Oosterholt, Sean, Pasqua, Oscar Della, Glass, Larry, Jones, Nancy E., Percy, Alan·2019·Neurology

DOI 10.1212/wnl.0000000000007316PMC PMC6550498

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE: To determine safety, tolerability, and pharmacokinetics of trofinetide and evaluate its efficacy in female children/adolescents with Rett syndrome (RTT), a debilitating neurodevelopmental condition for which no pharmacotherapies directed at core features are available. METHODS: This was a phase 2, multicenter, double-blind, placebo-controlled, parallel-group study, in which safety/tolerability, pharmacokinetics, and clinical response to trofinetide were characterized in 82 children/adolescents with RTT, aged 5 to 15 years. Sixty-two participants were randomized 1:1:1:1 to receive placebo twice a day (bid) for 14 days, followed by placebo, 50, 100, or 200 mg/kg bid of trofinetide for 42 days. Following blinded safety data review, 20 additional participants were randomized 1:1 to the 200 mg/kg or placebo bid groups. Safety assessments included adverse events, clinical laboratory tests, physical examinations, and concomitant medications. Clinician- and caregiver-based efficacy measurements assessed clinically relevant, phenotypic dimensions of impairment of RTT. RESULTS: All dose levels were well tolerated and generally safe. Trofinetide at 200 mg/kg bid showed statistically significant and clinically relevant improvements relative to placebo on the Rett Syndrome Behaviour Questionnaire, RTT-Clinician Domain Specific Concerns-Visual Analog Scale, and Clinical Global Impression Scale-Improvement. Exploratory analyses suggested that observed changes correlated with trofinetide exposure. CONCLUSION: These results, together with those from a previous adolescent/adult trial, indicate trofinetide's potential for treating core RTT symptoms and support further trials. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for children/adolescents with RTT, trofinetide was safe, well-tolerated, and demonstrated improvement over placebo at 200 mg/kg bid in functionally important dimensions of RTT.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000007316

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Study design (A) and participant disposition (B) BID = twice daily dosing; ITT = intention to treat; mITT = modified intention to treat; PK = pharmacokinetic.CC BY-NC-ND · PubMed Central

Figure 2 Core efficacy measures demonstrating improvement in the 200 mg/kg group compared to placebo (A) Change from treatment baseline of the 200 mg/kg group compared to placebo in the mITT population for the RSBQ total score. EOT measured at day 54. Posttreatment follow-up at day 66. Improvement is a decrease in score. LSmeans: placebo response included as covariate in the model. (B) Absolute values of the 200 mg/kg group compared to placebo in the mITT population for the CGI-I. EOT measured at day 54. Posttreatment follow-up at day 66. Improvement is lower score. LSmeans. (C) Change from treatment baseline of the 200 mg/kg group compared to placebo in the mITT population for the RTT-DSC. EOT measured at day 54. Posttreatment follow-up at day 66. Improvement is a decrease in score. Exact median test. Treatment baseline = day 14. CGI-I = Clinical Global Impression Scale–Improvement; EOT = end of treatment; LSmean = least-squares mean; mITT = modified intention to treat; RSBQ = Rett Syndrome Behaviour Questionnaire; RTT-DSC = Rett syndrome–Clinician Domain Specific Concerns; VAS = Visual Analog Scale.CC BY-NC-ND · PubMed Central

Figure 3 Relationship between change from treatment baseline in RBSQ, CGI-I, and RTT-DSC and trofinetide exposure Relationship between change from treatment baseline in RBSQ, CGI-I, and RTT-DSC and AUC0–12 at different visits and over the active treatment period. (A) Relationship between percentage change from treatment baseline in RSBQ-total score and AUC0–12 at day 28. (B) Relationship between percentage change from treatment baseline in RSBQ-total score and cumulative AUC during the active dosing period. (C) Relationship between CGI-I scores and AUC0–12 at day 28. (D) Relationship between CGI-I score and cumulative AUC during the active dosing period. (E) Relationship between percentage change from treatment baseline in RTT-DSC score and AUC0–12 at day 28. (F) Relationship between percentage change from treatment baseline in RTT-DSC score and cumulative AUC during the active dosing period. Visit 3 (day 14, end of placebo run-in), visit 4 (day 21), visit 5 (day 28), visit 6 (day 42), visit 7 (day 54, end of treatment), visit 8 (day 66, posttreatment). Solid lines are obtained by linear regression. Where applicable, placebo data (AUC = 0) from different visits are pooled together. AUC = area under the concentration vs time curve; CGI-I = Clinical Global Impression Scale–Improvement; RSBQ = Rett Syndrome Behaviour Questionnaire; RTT-DSC = Rett syndrome–Clinician Domain Specific Concerns.CC BY-NC-ND · PubMed Central

Figure 4 Cohen d effect sizes for the RSBQ and RTT-DSC-VAS (200 mg/kg vs placebo at day 54) Cohen d effect sizes for the RSBQ (A) and RTT-DSC-VAS (B). Cohen d values are unadjusted, that is, do not incorporate covariate information from treatment baseline or placebo response. bid = twice a day; RSBQ = Rett Syndrome Behaviour Questionnaire; RTT-DSC = Rett syndrome–Clinician Domain Specific Concerns; VAS = Visual Analog Scale.CC BY-NC-ND · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: Report of 35 cases
Hagberg, B. A., Aicardi, J. F., Dias, K., & Ramos, O. (1983) · Annals of Neurology · doi:10.1002/ana.410140412 · Cited by 1,515
Rett syndrome: Revised diagnostic criteria and nomenclature
Neul, J. L., Kaufmann, W. E., Glaze, D. G., Christodoulou, J., Clarke, A. J., Bahi‐Buisson, N., Leonard, H., Bailey, M. E. S., Schanen, N. C., Zappella, M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22124 · Cited by 1,437
Wild-type microglia arrest pathology in a mouse model of Rett syndrome
Derecki, N. C., Cronk, J. C., Lu, Z., Xu, E., Abbott, S. B. G., Guyenet, P. G., & Kipnis, J. (2012) · Nature · doi:10.1038/nature10907 · Cited by 607
Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice
Tropea, D., Giacometti, E., Wilson, N. R., Beard, C., McCurry, C., Fu, D. D., Flannery, R., Jaenisch, R., & Sur, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812394106 · Cited by 593
Specific mutations in Methyl-CpG-Binding Protein 2 confer different severity in Rett syndrome
Neul, J. L., Fang, P., Barrish, J., Lane, J., Caeg, E. B., Smith, E. O., Zoghbi, H., Percy, A., & Glaze, D. G. (2008) · Neurology · doi:10.1212/01.wnl.0000291011.54508.aa · Cited by 498
Self-citation
Rett syndrome in Australia: A review of the epidemiology
Laurvick, C. L., de Klerk, N. H., Bower, C. I., Christodoulou, J., Ravine, D., Ellaway, C., Williamson, S. L., & Leonard, H. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.10.037 · Cited by 345
Methyl-CpG-binding protein 2 ( MECP2 ) mutation type is associated with disease severity in Rett syndrome
Cuddapah, V. A., Pillai, R. B., Shekar, K. V., Lane, J. B., Motil, K. J., Skinner, S. A., Tarquinio, D. C., Glaze, D. G., McGwin, G., Kaufmann, W. E., et al. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2013-102113 · Cited by 311
Parent-Defined Target Symptoms Respond to Risperidone in RUPP Autism Study: Customer Approach to Clinical Trials
ARNOLD, L. E., VITIELLO, B., MCDOUGLE, C., SCAHILL, L., SHAH, B., GONZALEZ, N. M., CHUANG, S., DAVIES, M., HOLLWAY, J., AMAN, M. G., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200312000-00011 · Cited by 218
Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome
Khwaja, O., Ho, E., Barnes, K. V., O’Leary, H. M., Pereira, L. M., Finkelstein, Y., Nelson, C. A., Vogel‐Farley, V. K., DeGregorio, G., Holm, I. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311141111 · Cited by 212
The Rett Syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome
Mount, R. H., Charman, T., Hastings, R. P., Reilly, S., & Cass, H. (2002) · Journal of Child Psychology and Psychiatry · doi:10.1111/1469-7610.00236 · Cited by 190
Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers
Danhof, M., Alván, G., Dahl, S. G., Kuhlmann, J., & Paintaud, G. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-5882-3 · Cited by 164
Developmental delay in Rett syndrome: data from the natural history study
Neul, J. L., Lane, J. B., Lee, H. S., Geerts, S. P., Barrish, J. O., Annese, F., Baggett, L., Barnes, K., Skinner, S. A., Motil, K. J., et al. (2014) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-6-20 · Cited by 159
What is the right dose for children?
Cella, M., Knibbe, C. A. J., Danhof, M., & Pasqua, O. E. D. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03591.x · Cited by 155
Rett Syndrome: Crossing the Threshold to Clinical Translation
Katz, D. M., Bird, A., Coenraads, M., Gray, S. J., Menon, D. U., Philpot, B. D., & Tarquinio, D. C. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2015.12.008 · Cited by 150
Rett syndrome diagnostic criteria: Lessons from the Natural History Study
Percy, A. K., Neul, J. L., Glaze, D. G., Motil, K. J., Skinner, S. A., Khwaja, O., Lee, H., Lane, J. B., Barrish, J. O., Annese, F., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22154 · Cited by 144
Self-citation
Recent advances in MeCP2 structure and functionThis paper is one of a selection of papers published in this Special Issue, entitled 29th Annual International Asilomar Chromatin and Chromosomes Conference, and has undergone the Journal’s usual peer review process.
Hite, K. C., Adams, V. H., & Hansen, J. C. (2009) · Biochemistry and Cell Biology · doi:10.1139/o08-115 · Cited by 132
The Changing Face of Survival in Rett Syndrome and MECP2-Related Disorders
Tarquinio, D. C., Hou, W., Neul, J. L., Kaufmann, W. E., Glaze, D. G., Motil, K. J., Skinner, S. A., Lee, H. S., & Percy, A. K. (2015) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2015.06.003 · Cited by 129
DNA methylation and Rett syndrome
Kriaučionis, S., & Bird, A. P. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg286 · Cited by 128
Rett syndrome and associated movement disorders
FitzGerald, P. M., Jankovic, J. J., & Percy, A. K. (1990) · Movement Disorders · doi:10.1002/mds.870050303 · Cited by 125
Social impairments in Rett syndrome: characteristics and relationship with clinical severity
Kaufmann, W. E., Tierney, E., Rohde, C. A., Suarez‐Pedraza, M. C., Clarke, M. A., Salorio, C. F., Bibat, G., Bukelis, I., Naram, D., Lanham, D. C., et al. (2011) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2011.01404.x · Cited by 124
Longevity in Rett Syndrome: Analysis of the North American Database
Kirby, R. S., Lane, J. B., Childers, J., Skinner, S. A., Annese, F., Barrish, J. O., Glaze, D. G., MacLeod, P., & Percy, A. K. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2009.07.015 · Cited by 109
A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome
Glaze, D. G., Neul, J. L., Percy, A. K., Feyma, T. J., Beisang, A., Yaroshinsky, A., Stoms, G. B., Zuchero, D., Horrigan, J. P., Glass, L., et al. (2017) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2017.07.002 · Cited by 104
A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of fragile X syndrome
Berry-Kravis, E., Horrigan, J. P., Tartaglia, N., Hagerman, R., Kolevzon, A., Erickson, C. A., Hatti, S., Snape, M., Yaroshinsky, A., Stoms, G., et al. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.04.019 · Cited by 102
Self-citation
Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales
Barnes, K. V., Coughlin, F., O’Leary, H. M., Bruck, N. M., Bazin, G. A., Beinecke, E. B., Walco, A. C., Cantwell, N. G., & Kaufmann, W. E. (2015) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-015-9127-4 · Cited by 95
Improving Treatment Trial Outcomes for Rett Syndrome
Neul, J. L., Glaze, D. G., Percy, A. K., Feyma, T. J., Beisang, A., Dinh, T., Suter, B., Anagnostou, E. A., Snape, M., Horrigan, J. P., et al. (2015) · Journal of Child Neurology · doi:10.1177/0883073815579707 · Cited by 85
NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats
Wei, H. H., Lu, X. M., Shear, D. A., Waghray, A., Yao, C., Tortella, F. C., & Dave, J. R. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-19 · Cited by 83
Placebo‐controlled crossover assessment of mecasermin for the treatment of Rett syndrome
O’Leary, H. M., Kaufmann, W. E., Barnes, K. V., Rakesh, K., Kapur, K., Tarquinio, D. C., Cantwell, N. G., Roche, K. J., Rose, S. A., Walco, A. C., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.533 · Cited by 83
The association between behavior and genotype in Rett syndrome using the Australian Rett Syndrome Database
Robertson, L., Hall, S. E., Jacoby, P., Ellaway, C., de Klerk, N. H., & Leonard, H. (2006) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30270 · Cited by 72
The Incidence of Rett Syndrome in France
Bienvenu, T., Philippe, C., de Roux, N., Raynaud, M., Bonnefont, J., Pasquier, L., Lesca, G., Mancini, J., Jonveaux, P., Moncla, A., et al. (2006) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.10.013 · Cited by 57
Insulin-like growth factor 1 (IGF1) and its active peptide (1–3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms
Corvin, A. P., Molinos, I., Little, G., Donohoe, G., Gill, M., Morris, D. W., & Tropea, D. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.05.029 · Cited by 57
A national survey of Rett syndrome: behavioural characteristics
Cianfaglione, R., Clarke, A. J., Kerr, M., Hastings, R. P., Oliver, C., Moss, J. F., Heald, M., & Felce, D. (2015) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-015-9104-y · Cited by 56
Neurobiologically-based treatments in Rett syndrome: opportunities and challenges
Kaufmann, W. E., Stallworth, J. L., Everman, D. B., & Skinner, S. A. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1229181 · Cited by 51
Aspects of speech‐language abilities are influenced by MECP2 mutation type in girls with Rett syndrome
Urbanowicz, A., Downs, J. A., Girdler, S. J., Ciccone, N., & Leonard, H. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36871 · Cited by 36
NNZ-2566, a Glypromate Analog, Attenuates Brain Ischemia-Induced Non-Convulsive Seizures in Rats
Lu, X. M., Si, Y., Williams, A. J., Hartings, J. A., Gryder, D. S., & Tortella, F. C. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.109 · Cited by 34
Ageing in Rett syndrome
Cianfaglione, R., Clarke, A. R., Kerr, M., Hastings, R. P., Oliver, C., & Felce, D. (2015) · Journal of Intellectual Disability Research · doi:10.1111/jir.12228 · Cited by 26
Adaptive trials in paediatric development: dealing with heterogeneity and uncertainty in pharmacokinetic differences in children
Cella, M., Danhof, M., & Pasqua, O. E. D. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04187.x · Cited by 19
Covariate effects and population pharmacokinetics of lamivudine in HIV ‐infected children
Piana, C., Zhao, W., Adkison, K. K., Burger, D. M., Jacqz-Aigrain, É., Danhof, M., & Pasqua, O. E. D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12247 · Cited by 18
Prevalence study of Rett syndrome in North Dakota children
Burd, L., Vesley, B., Martsolf, J. T., & Kerbeshian, J. (1991) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320380414 · Cited by 18
Rett Syndrome: Coming to Terms with Treatment
Percy, A. K. (2014) · Advances in Neuroscience · doi:10.1155/2014/345270 · Cited by 17
Population pharmacokinetics of NNZ‐2566 in healthy subjects
Oosterholt, S., Horrigan, J., Jones, N. E., Glass, L., & Pasqua, O. D. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.032 · Cited by 14
Biomarker exposure–response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX‐2 inhibitor
Taneja, A., Oosterholt, S. P., Danhof, M., & Pasqua, O. E. D. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.629 · Cited by 7

Sorted by citations

An Update on Psychopharmacological Treatment of Autism Spectrum Disorder
Aishworiya, R., Valica, T., Hagerman, R., & Restrepo, B. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01183-1 · Cited by 233
“Trofinetide is glycyl-L-2-methylprolylL-glutamic acid, and it was studied in a controlled phase 2 trial in 82 children with Rett syndrome ages 5 to 15 years, and significant benefit was found in the high-dose group (200 mg/kg/day) compared to placebo [137].”
Background
The role of GABAergic signalling in neurodevelopmental disorders
Tang, X., Jaenisch, R., & Sur, M. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-021-00443-x · Cited by 221
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study
Neul, J. L., Percy, A. K., Benke, T. A., Berry‐Kravis, E., Glaze, D. G., Marsh, E. D., Lin, T., Stankovic, S., Bishop, K. M., & Youakim, J. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02398-1 · Cited by 211
Advances in understanding of Rett syndrome and MECP2 duplication syndrome: prospects for future therapies
Sandweiss, A. J., Brandt, V. L., & Zoghbi, H. Y. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30217-9 · Cited by 179
Global prevalence of Rett syndrome: systematic review and meta-analysis
Petriti, U., Dudman, D. C., Scosyrev, E., & López‐León, S. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02169-6 · Cited by 128

See all 163

Authors: Glaze, D. G., Neul, J. L., Kaufmann, W. E., Berry-Kravis, E., Condon, S., Stoms, G., Oosterholt, S., Della Pasqua, O., Glass, L., Jones, N. E., Percy, A. K., Rett 002 Study Group, Glaze, D. G., Neul, J. L., Kaufmann, W. E., Berry-Kravis, E., Condon, S., Stoms, G., Oosterholt, S., Pasqua, O. D., Glass, L., Jones, N. E., & Percy, A.
Affiliations: From the Department of Pediatrics and Neurology (D.G.G.), Baylor College of Medicine, Houston, TX; Department of Neurosciences (J.L.N.), University of California, San Diego; Greenwood Genetic Center (W.E.K.), Center for Translational Research, Greenwood, SC; Pediatrics, Neurological Sciences, and Biochemistry (E.B.K.), Rush University Medical Center, Chicago, IL;Vital Systems, Inc. (S.C., G.S.), Rolling Meadows, IL; Clinical Pharmacology & Therapeutics Group (S.O., O.D.P.), University College...
Rush University Medical Center (US)
ORCID: Della Pasqua, Oscar
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2019-04-16
Volume: 92
Issue: 16
Pages: e1912-e1925
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.0000000000007316
PMC: PMC6550498
OpenAlex: W2922881551
Cited by: 160
References: 42
Citations by year: 2026: 8 · 2025: 14 · 2024: 46 · 2023: 33 · 2022: 14 · 2021: 15 · 2020: 22 · 2019: 6
FWCI: 8.59
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
Locations: Neurology (publishedVersion, cc-by-nc-nd)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD083211)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: trofinetide, Rett syndrome, pediatric patients, safety and tolerability, pharmacokinetics, neurodevelopmental disorders, symptom improvement, Clinical Global Impression Scale, dose-response relationship
MeSH terms: Adolescent, Anti-Inflammatory Agents, Non-Steroidal, Child, Child, Preschool, Double-Blind Method, Female, Glutamates, Humans, Rett Syndrome, Treatment Outcome, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks